Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00311428
Status:
COMPLETED
Last Update Posted:
2006-09-14
First Post:
2006-04-03
Brief Title:
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to 36 Months
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase IV Observer-Blind Randomized Parallel Groups Single-Center Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 025 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to 36 Months
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase IV protocol is designed to evaluate the safety clinical tolerability and immunogenicity of the 2005-2006 formulation of three widely used conventional influenza vaccines in children aged 6 to 35 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2004-001952-35 | None | None | None |